Exact Sciences Corporation
EXAS
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Testā¦ read more
Healthcare
Diagnostics & Research
24 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$101.45
Price+0.32%
$0.32
1Y
Price
Market Cap
$19.222b
Large
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years+4.5%
EBITDA Margin-2.3%
Net Profit Margin+22.3%
Free Cash Flow MarginRevenue
$3.082b
+11.7%
1y CAGR+14.0%
3y CAGR+15.0%
5y CAGREarnings
-$986.579m
+4.1%
1y CAGR-110.9%
3y CAGR-84.3%
5y CAGREPS
-$5.32
+4.8%
1y CAGR-107.3%
3y CAGR-80.9%
5y CAGRBook Value
$2.501b
$5.900b
Assets$3.399b
Liabilities$2.535b
DebtDebt to Assets
43.0%
-3.3x
Debt to EBITDAFree Cash Flow
$247.083m
+231.5%
1y CAGR+157.4%
3y CAGR+97.0%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company